StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3058% above fair value
$3.41−0.04 (-1.16%)

Close on Nov 16, 2026Market cap $272.13MP/E –Yield –

Prelude Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Prelude Therapeutics's price to book ratio was 2.4× on Nov 11, 2026, against 2.2× a year earlier. Over the last 5 years it ranged from 0.3× to 7.0×, with a median of 1.2×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.4×−1.4
2025Dec 31, 20253.8×+3.2
2024Dec 31, 20240.6×−0.4
2023Dec 29, 20231.0×−0.3
2022Dec 30, 20221.3×+0.7
2021Jan 29, 20210.6×−0.1
2020Dec 31, 20200.7×–

More Prelude Therapeutics figures

See a number that looks wrong?